Ubs Asset Management Americas Inc Protagonist Therapeutics, Inc Transaction History
Ubs Asset Management Americas Inc
- $345 Billion
- Q2 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 369,955 shares of PTGX stock, worth $17.6 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
369,955
Previous 335,318
10.33%
Holding current value
$17.6 Million
Previous $9.7 Million
32.14%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding PTGX
# of Institutions
212Shares Held
59.1MCall Options Held
19KPut Options Held
107K-
Farallon Capital Management LLC San Francisco, CA5.84MShares$278 Million0.98% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$274 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.29MShares$252 Million3.06% of portfolio
-
Bvf Inc San Francisco, CA3.32MShares$158 Million3.52% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.24MShares$154 Million0.0% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $2.34B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...